Overview

A Study to Evaluate the Pharmacokinetics and Safety Between Single Oral Administration of BR3006 and Co-administration of BR3006A, BR3006B and BR3006C in Healthy Adult Volunteers Under Fasting Conditions

Status:
COMPLETED
Trial end date:
2025-01-03
Target enrollment:
Participant gender:
Summary
The purpose of this clinical study is to evaluate the pharmacokinetics and safety between single oral administration of BR3006 and co-administration of BR3006A, BR3006B and BR3006C in healthy adult volunteers under fasting conditions
Phase:
PHASE1
Details
Lead Sponsor:
Boryung Pharmaceutical Co., Ltd